Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Acacia Pharma 2021

8.462 Posts
Pagina: «« 1 ... 312 313 314 315 316 ... 424 »» | Laatste | Omlaag ↓
  1. forum rang 4 Sirlander 19 augustus 2021 09:28


    Acacia Pharma has updated the market on the significant ongoing progress of US formulary wins for BARHEMSYS for the treatment and prevention of post-operative nausea and vomiting (PONV) and BYFAVO, an intravenous sedative for use during invasive medical procedures. Formulary access is key for initial sales in the hospital setting and early BARHEMSYS sales should start to trickle through by end FY21/early FY22, while the focus for BYFAVO remains on formulary wins. Obtaining wide formulary adoption is critical and should translate to significant revenue generation from FY22 and maiden operating profit from FY23. Our valuation of Acacia Pharma is unchanged at €1,278m.
8.462 Posts
Pagina: «« 1 ... 312 313 314 315 316 ... 424 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 874,02 -0,09%
EUR/USD 1,0689 -0,12%
FTSE 100 8.040,38 -0,06%
Germany40^ 18.063,80 -0,41%
Gold spot 2.325,12 +0,13%
NY-Nasdaq Composite 15.696,64 +1,59%

Stijgers

VIVORY...
+24,31%
ASMI
+10,99%
BESI
+4,08%
NX FIL...
+3,85%
TomTom
+3,80%

Dalers

ALLFUN...
-11,00%
ING
-5,96%
Flow T...
-2,94%
WDP
-2,89%
RELX
-2,04%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links